摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(3,5-二甲氧基苯基)庚烷-1-酮 | 39192-51-3

中文名称
1-(3,5-二甲氧基苯基)庚烷-1-酮
中文别名
(3,5-二甲氧基苯基)己基酮;1-(3,5-二甲氧基-苯基)-1-庚酮
英文名称
1-(3,5-dimethoxyphenyl)heptan-1-one
英文别名
1-(3,5-Dimethoxy-phenyl)-heptan-1-on
1-(3,5-二甲氧基苯基)庚烷-1-酮化学式
CAS
39192-51-3
化学式
C15H22O3
mdl
——
分子量
250.338
InChiKey
FMEATOMLFIVSDA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    26-30 °C(lit.)
  • 沸点:
    161-161.5 °C(Press: 3 Torr)
  • 密度:
    1.017 g/mL at 25 °C(lit.)
  • 闪点:
    230 °F

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    18
  • 可旋转键数:
    8
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xn
  • 海关编码:
    2914509090
  • 危险品运输编号:
    UN 2811 6.1/PG 3
  • 包装等级:
    III
  • 危险类别:
    6.1
  • 危险性防范说明:
    P280,P301+P310
  • 危险性描述:
    H301,H317,H413

SDS

SDS:3049ebad607ce6ce6ed1eaf737306554
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    大麻素侧链的药理学要求。在C1'处探测大麻素受体亚位点。
    摘要:
    我们实验室的早期工作为CB1和CB2大麻素受体结合域内存在一个亚位点提供了证据,该位点对应于经典大麻素苄基侧链位置的取代基。现在已经通过合成一系列带有C1'-环取代基的(-)-Delta(8)-四氢大麻酚类似物来探索该亚位点的存在和立体化学特征。在本文所述的化合物中,具有C1'-二硫杂环戊烷(1c),C1'-二氧戊环(2d)和环戊基(2a)取代基的化合物表现出对CB1和CB2的最高亲和力。我们使用分子建模方法更好地定义了假定亚位点的立体化学极限。体外药理测试发现1c是有效的CB1激动剂。
    DOI:
    10.1021/jm020558c
  • 作为产物:
    描述:
    1-(3,5-dimethoxyphenyl)-1-heptanolchromium(VI) oxide硫酸 作用下, 以 丙酮 为溶剂, 反应 0.5h, 以79.6%的产率得到1-(3,5-二甲氧基苯基)庚烷-1-酮
    参考文献:
    名称:
    Pharmacophoric Requirements for Cannabinoid Side Chains:  Multiple Bond and C1‘-Substituted Δ8-Tetrahydrocannabinols
    摘要:
    Accumulated evidence indicates that within the cannabinoid structure the aliphatic side chain plays a pivotal role in determining cannabimimetic activity. We describe the synthesis and affinities for the CB1 and CB2 receptors of a series of novel Delta(8)-THC analogues in which the side-chain pharmacophores are conformationally more defined than in the parent molecule. No analogue has the side-chain pharmacophore in a fully restricted conformation. However, our design serves to narrow down the scope of options for conformational requirements at the receptor active sites. All the analogues tested showed nanomolar or subnanomolar affinities for the receptors; 2-(6a,7,10,10a-tetrahydro-6,6,9-trimethyl-1-hydroxy-6H-dibenzo[b,d]pyranyl)- 2-hexyl-1,3-dithiolane was found to possess very high affinity for both cannabinoid receptors(CB1, K-i = 0.32 nM; CB2, K-i = 0.52 nM).
    DOI:
    10.1021/jm970277i
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] NOUVELLES MÉTHODES DE TRAITEMENT DES MALADIES INFLAMMATOIRES
    申请人:CORTICAL PTY LTD
    公开号:WO2004089927A1
    公开(公告)日:2004-10-21
    Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as a part of combination therapy. Novel compounds of formula (I) are also provided for.
    提供了抑制巨噬细胞迁移抑制因子(MIF)细胞因子或生物活性的方法,包括将MIF与式(I)化合物接触。该发明还涉及治疗MIF细胞因子或生物活性参与的疾病或病况的方法,包括给予式(I)化合物的治疗,可以单独使用或作为联合疗法的一部分。还提供了式(I)的新化合物。
  • [EN] NOVEL CANNABINERGIC COMPOUNDS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS CANNABINERGIQUES ET LEURS UTILISATIONS
    申请人:UNIV NORTHEASTERN
    公开号:WO2014039042A1
    公开(公告)日:2014-03-13
    Disclosed are compounds and compositions that modulate cannabinoid receptors, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors. This disclosure is directed to methods of treating cannabinoid dependence, neuropathy, inflammation, glaucoma, a neurodegenerative disorder, a motor function disorder, a gastrointestinal disorder, hypothermia, emesis, loss of appetite, or anorexia associated with AIDS.
    本发明涉及调节大麻素受体的化合物和组合物、调节大麻素受体的方法以及治疗与调节大麻素受体有关的各种疾病的方法。本公开涉及治疗大麻素依赖、神经病变、炎症、青光眼、神经退行性疾病、运动功能障碍、胃肠道疾病、低温、呕吐、食欲不振或艾滋病相关的厌食症的方法。
  • Novel methods for the treatment of inflammatory diseases
    申请人:Morand Francis Eric
    公开号:US20070010563A1
    公开(公告)日:2007-01-11
    Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as a part of combination therapy. Novel compounds of formula (I) are also provided for.
    本发明提供了抑制巨噬细胞迁移抑制因子(MIF)细胞因子或生物活性的方法,包括将MIF与式(I)化合物接触。本发明还涉及治疗MIF细胞因子或生物活性涉及的疾病或病症的方法,包括单独或作为联合治疗的一部分给予式(I)化合物。本发明还提供了新的式(I)化合物。
  • Methods for the treatment of inflammatory diseases
    申请人:Cortical PTY LTD
    公开号:US07863313B2
    公开(公告)日:2011-01-04
    Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as a part of combination therapy. Novel compounds of formula (I) are also provided for.
    提供了抑制细胞因子或巨噬细胞迁移抑制因子(MIF)生物活性的方法,包括将MIF与式(I)的化合物接触。本发明还涉及治疗MIF细胞因子或生物活性参与的疾病或病况的方法,包括单独或作为联合治疗的一部分给予式(I)的化合物。还提供了式(I)的新化合物。
  • Novel Methods for the Treatment of Inflammatory Diseases
    申请人:Morand Eric Francis
    公开号:US20100324001A1
    公开(公告)日:2010-12-23
    Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as a part of combination therapy. Novel compounds of formula (I) are also provided for.
    本发明提供了抑制巨噬细胞迁移抑制因子(MIF)的细胞因子或生物活性的方法,包括使用式(I)的化合物接触MIF。本发明还涉及治疗MIF细胞因子或生物活性参与的疾病或病症的方法,包括单独或作为联合治疗的一部分给予式(I)的化合物。本发明还提供了新的式(I)化合物。
查看更多